Short‑term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion.

IF 1.9 3区医学 Q2 OPHTHALMOLOGY

Japanese Journal of Ophthalmology Pub Date : 2025-06-27 DOI:10.1007/s10384-025-01237-9

Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi

{"title":"Short‑term outcomes of switching to faricimab for macular edema secondary to retinal vein occlusion.","authors":"Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi","doi":"10.1007/s10384-025-01237-9","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluated the anatomical and functional outcomes in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) who were switched from conventional anti-vascular endothelial growth factor (VEGF) agents to faricimab.Study design: Retrospective observational study.Methods: This study included 42 eyes from 42 patients treated at Hikichi Eye Clinic between April and August 2024. All patients had relapsed ME despite prior treatment with aflibercept and were switched to intravitreal faricimab (6.0 mg). The primary endpoints included best-corrected visual acuity (BCVA), central foveal thickness (CFT), and intravitreal injection intervals over six months.Results: The mean (± standard error) CFT significantly decreased from 356 ± 23 μm to 214 ± 3 μm at one month (p < 0.01) and remained stable at the final visit (205 ± 4 μm). Logarithm of the minimum angle of resolution (logMAR) BCVA improved from 0.16 ± 0.03 to 0.04 ± 0.03 at one month (p < 0.01) and remained at 0.02 ± 0.02 at the final visit. The mean injection interval was significantly extended from 12.3 ± 0.4 weeks to 16.2 ± 0.5 weeks (p < 0.01).Conclusion: Faricimab improved anatomical and functional outcomes while extending treatment intervals in ME secondary to RVO. Further large-scale, prospective, and long-term follow-up studies are needed to confirm these findings.","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10384-025-01237-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluated the anatomical and functional outcomes in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) who were switched from conventional anti-vascular endothelial growth factor (VEGF) agents to faricimab.

Study design: Retrospective observational study.

Methods: This study included 42 eyes from 42 patients treated at Hikichi Eye Clinic between April and August 2024. All patients had relapsed ME despite prior treatment with aflibercept and were switched to intravitreal faricimab (6.0 mg). The primary endpoints included best-corrected visual acuity (BCVA), central foveal thickness (CFT), and intravitreal injection intervals over six months.

Results: The mean (± standard error) CFT significantly decreased from 356 ± 23 μm to 214 ± 3 μm at one month (p < 0.01) and remained stable at the final visit (205 ± 4 μm). Logarithm of the minimum angle of resolution (logMAR) BCVA improved from 0.16 ± 0.03 to 0.04 ± 0.03 at one month (p < 0.01) and remained at 0.02 ± 0.02 at the final visit. The mean injection interval was significantly extended from 12.3 ± 0.4 weeks to 16.2 ± 0.5 weeks (p < 0.01).

Conclusion: Faricimab improved anatomical and functional outcomes while extending treatment intervals in ME secondary to RVO. Further large-scale, prospective, and long-term follow-up studies are needed to confirm these findings.

查看原文本刊更多论文

改用法昔单抗治疗继发性视网膜静脉阻塞黄斑水肿的短期疗效。

目的：本研究评估视网膜静脉阻塞（RVO）继发黄斑水肿（ME）患者从常规抗血管内皮生长因子（VEGF）药物切换到法利昔单抗的解剖和功能结果。研究设计：回顾性观察性研究。方法：本研究纳入了2024年4月至8月在Hikichi眼科诊所接受治疗的42例患者的42只眼睛。所有患者都复发了ME，尽管之前用阿非利西普治疗，并改为玻璃体内法利西单抗（6.0 mg）。主要终点包括最佳矫正视力（BCVA）、中央中央凹厚度（CFT）和玻璃体注射间隔超过6个月。结果：平均（±标准误差）CFT在1个月时由356±23 μm降至214±3 μm (p < 0.01)，并在最后一次随访时保持稳定（205±4 μm）。最小分辨角（logMAR） BCVA的对数在1个月时从0.16±0.03提高到0.04±0.03 (p < 0.01)，在最后一次访问时保持在0.02±0.02。平均注射间隔由12.3±0.4周显著延长至16.2±0.5周（p < 0.01）。结论：Faricimab改善了解剖学和功能结果，同时延长了RVO继发ME的治疗间隔。需要进一步的大规模、前瞻性和长期随访研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Ophthalmology 医学-眼科学

CiteScore

4.80

自引率

8.30%

发文量

审稿时长

6-12 weeks

期刊介绍： The Japanese Journal of Ophthalmology (JJO) was inaugurated in 1957 as a quarterly journal published in English by the Ophthalmology Department of the University of Tokyo, with the aim of disseminating the achievements of Japanese ophthalmologists worldwide. JJO remains the only Japanese ophthalmology journal published in English. In 1997, the Japanese Ophthalmological Society assumed the responsibility for publishing the Japanese Journal of Ophthalmology as its official English-language publication. Currently the journal is published bimonthly and accepts papers from authors worldwide. JJO has become an international interdisciplinary forum for the publication of basic science and clinical research papers.